Gyre Therapeutics, Inc. (GYRE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 6.56 |
| Open | 6.55 |
| Day High | 6.59 |
| Day Low | 6.32 |
| 52-Week High | 9.42 |
| 52-Week Low | 5.44 |
| Volume | 33,460 |
| Average Volume | 94,593 |
| Market Cap | 586.73M |
| PE | 91.71 |
| EPS | 0.07 |
| Moving Average 50 Days | 6.44 |
| Moving Average 200 Days | 7.4 |
| Change | -0.14 |
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
Gyre Pharmaceuticals completed a Pre-NDA meeting with China’s CDE, which agreed that the existing Phase 3 clinical data support a conditional approval filing for Hydronidone and priority review eligibility, subject to formal approval.Gyre Pharmaceuti
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
GlobeNewswire Inc.
Oct 15, 2025 11:00 AM GMT
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announc
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, toda